PGEN: Precigen Inc Company Value to Net Income

Precigen Corp - graphic logo of issuer PGEN

The volatility of Precigen, Inc. (PGEN) shares is driven by the ambitious developments of elite geneticists, as confirmed by the price-to-earnings ratio dynamics. Stability is maintained by management's skillful allocation of funds to accelerate the commercialization of therapies. Meanwhile, strict austerity and a focus on R&D testing mitigate risks. The 69.20 indicator expresses today's metric value, determining investors' current willingness to buy the company's future earnings.

Precigen (PGEN) Price to Earnings Ratio: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Intrexon (PGEN)

- price and consensus price forecast:
Stock Price precigen.com|PGEN - Consensus Target
- market capitalization information:
Market Value Precigen, Inc.|PGEN - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Precigen|PGEN - Company Book Value|Market Cap to Net Assets Ratio precigen.com|PGEN - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Precigen, Inc.|PGEN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Precigen Corp|PGEN - Company Debts|Debt to Book Value Ratio Precigen, Inc.|PGEN - Company Long-Term Debts|Short-Term Debt Precigen|Critical Liquidity Ratio precigen.com
- earnings and market multiples details:
PGEN - Company Net Income|Expected Net Income Precigen, Inc.|PGEN - P/E Multiple|Projected Price to Earnings Ratio Precigen Inc|PGEN - PEG Multiple|Enterprise Value to EBITDA Ratio Precigen, Inc.|PGEN - Operating profit EBITDA|Net earnings per share for the last four quarters Precigen|PGEN - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year precigen.com|PGEN - Earnings growth in current year|Expected net earnings per share growth next year Precigen, Inc.
Comprehensive company analysis:precigen.com PGEN
Signature product of Intrexon

The P/E ratio determines the market value of one unit of net profit, reflecting investors' willingness to pay a premium for future business growth. In the case of Precigen, Inc. (PGEN), the company's quarterly P/E demonstrates how the market values the potential of its patented cancer cell therapy technologies amid rigorous FDA reviews, allowing for the timely identification of asset overvaluation or the undervaluation of its innovative advantages.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL - Price to Earnings Ratio|Market Cap to Net Income TRML|Pharming Group N.V. (PHAR) - Price to Earnings Ratio|nektar.com - Company Value to Net Income|UPB (Upstream Bio) - P/E Multiple|Market Cap to Earnings Zenas Bio ZBIO|P/E Multiple IMNM|Price to Earnings Ratio Gossamer Bio Corp. GOSS|P/E Multiple KALV (KalVista Pharmaceuticals)|Business Payback Period septerna.com (SEPN)|Pieris Pharmaceuticals, Inc. - P/E Multiple|Market Cap to Net Income Ratio Savara Inc (SVRA)|RIGL: P/E Multiple|Market Cap to Earnings AnaptysBio Inc. (ANAB)|Price to Earnings Ratio Astria Therapeutics|Price to Earnings Multiple ENGN (engene.com)|Price to Earnings Ratio RAPT (RAPT Therapeutics)|JBIO (aerovatetx.com) - Company Value to Net Income|P/E Multiple ACRS (Aclaris)|Business Payback Period Kyverna Therapeutics, Inc (KYTX)|TLSA - Price to Earnings Ratio|CABA (cabalettabio.com) - Price to Earnings Multiple|VTYX: P/E Multiple|Price to Earnings Ratio Theratechnologies, Inc.|Price to Earnings Ratio AVTX|Eledon Pharmaceuticals, Inc (ELDN) - Business Payback Period|Price to Earnings Ratio Agenus (AGEN)|CLYM: Market Cap to Net Income|P/E Multiple ZURA (Zura Bio)|Market Cap to Net Income Ratio aTyr Pharma Inc|Adagene Corp - P/E Multiple|Market Cap to Earnings ImageneBio Inc|shattucklabs.com (STTK) - Price to Earnings Ratio|Price to Earnings Multiple EQ|Price to Earnings Ratio Connect Biopharma Holdings|Immunic Inc - Market Cap to Net Income|P/E Multiple ATRA|IFRX (inflarx.de) - Company Value to Net Income|P/E Multiple XFOR (X4 Pharmaceuticals)|P/E Multiple Adicet Bio Inc. ACET|CELU - Price to Earnings Ratio|Company Value to Net Income INMB (INmune Bio Inc)|Barinthus Bio (BRNS) - Price to Earnings Ratio|Price to Earnings Ratio Kezar Life Sciences Inc|SABS (SAB Biotherapeutics) - P/E Multiple|P/E Multiple akaritx.com|Price to Earnings Ratio ENLV (Enlivex Therapeutics)|QTTB (q32bio.com) - Company Value to Net Income|P/E Multiple GOVX (GeoVax Labs Inc)|Business Payback Period Edesa Biotech Corp (EDSA)|IBIO - Price to Earnings Ratio|Carisma Therapeutics (CARM) - Price to Earnings Ratio|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Ratio Bolt Biotherapeutics, Inc.|Price to Earnings Ratio HCWB|P/E Multiple Aptevo|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|aditxt.com - Price to Earnings Multiple|P/E Multiple GRI (GRI Bio)|XORTX Therapeutics Inc (XRTX) - Market Cap to Earnings|HIND - Price to Earnings Ratio|Market Cap to Net Income REVB|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|scinai.com - Company Value to Net Income|CALI (CalciMedica Inc) - P/E Multiple|Market Cap to Earnings Affimed Therapeutics AFMD|P/E Multiple ALLK|Price to Earnings Ratio hookipapharma.com HOOK|P/E Multiple IGMS (IGM Biosciences)|Business Payback Period iteostherapeutics.com (ITOS)|Ocean Biomedical - P/E Multiple|Market Cap to Net Income Ratio TC BioPharm (Holdings) Plc (TCBP)|THRD: P/E Multiple